Self-pay options for Ozempic without insurance

If you’ve heard about the breakthrough weight-loss results from medications like Wegovy, Ozempic, or Mounjaro, you’re not alone. These GLP-1 drugs have transformed weight management for millions—but there’s one major catch: insurance coverage is complex, often restricted, and varies wildly depending on your plan and state.

Whether you have commercial insurance, Medicare, or Medicaid, understanding what’s covered (and what’s not) can save you thousands of dollars and weeks of frustration. In this comprehensive guide, we’ll break down exactly how insurance handles these medications, who qualifies for coverage, what to do if you’re denied, and the best self-pay options available in 2025.

Understanding GLP-1 Medications: What Are We Talking About?

Before diving into insurance details, let’s clarify what these medications actually are and how they differ:

Wegovy (Semaglutide for Weight Loss)

FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight with weight-related conditions (BMI ≥27). Wegovy is the same active ingredient as Ozempic, but formulated and approved explicitly for weight loss. It works by mimicking a hormone that regulates appetite and food intake, leading to significant weight reduction—clinical trials showed an average of 15% body weight loss over 68 weeks.

Ozempic (Semaglutide for Type 2 Diabetes)

FDA-approved for Type 2 diabetes management, not weight loss. However, weight loss is a common side effect, which has led to widespread off-label use for obesity. Insurance companies are keenly aware of this and typically only cover Ozempic when prescribed for diabetes, not for weight management alone.

Mounjaro (Tirzepatide for Type 2 Diabetes)

FDA-approved for Type 2 diabetes, Mounjaro is a dual GIP/GLP-1 receptor agonist—a newer mechanism showing even more impressive weight loss than single GLP-1 drugs. Like Ozempic, it’s covered for diabetes but not for off-label weight loss (Eli Lilly’s weight-loss version, Zepbound, faces the same coverage challenges as Wegovy).

The key takeaway: Insurance treats diabetes medications very differently from weight-loss drugs, even when they’re the same molecule.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Does Commercial Insurance Cover These Medications?

The Short Answer: It Depends—Heavily

Most commercial health plans in 2025 fall into one of three categories:

1. Cover diabetes medications (Ozempic, Mounjaro) but exclude weight-loss drugs (Wegovy)
This is the most common scenario. If you have Type 2 diabetes and your doctor prescribes Ozempic or Mounjaro, your plan will likely cover it—though you’ll still need to jump through prior authorization hoops. But if you want Wegovy for weight management without diabetes, many employer plans simply exclude it as a non-essential benefit.

2. Cover weight-loss medications with strict restrictions
Some progressive employers and plans (often large corporations or unions) do cover Wegovy, but with rigorous criteria: BMI above 30 (or 27 with comorbidities like hypertension or sleep apnea), documented proof of 6+ months of supervised diet and exercise attempts, and sometimes requirements to try cheaper weight-loss medications first.

3. Exclude all anti-obesity drugs as optional benefits
Many insurers consider weight-loss drugs ‘optional’ and too expensive to justify, given the $1,000+ monthly cost. Even when FDA-approved and medically necessary, these plans won’t cover them.

Prior Authorization: The Gatekeeper

Nearly every insurance plan that covers these medications requires prior authorization (PA). Here’s what that typically involves:

For Wegovy (weight loss):

• Documentation of BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (diabetes, hypertension, high cholesterol, or sleep apnea)
• Proof of at least 6 months of physician-supervised lifestyle intervention (diet and exercise program)
• Sometimes proof of trying older weight-loss medications (like phentermine or orlistat) first
• Age requirement (typically 18+, though some plans cover pediatric use under specific criteria)
• Periodic re-evaluation (often every 3-6 months) to confirm you’re losing weight—if you don’t hit targets like 5% weight loss, coverage may be discontinued

For Ozempic/Mounjaro (diabetes):

• Confirmed Type 2 diabetes diagnosis with lab results (A1c levels)
• Documentation of trying first-line diabetes medications (like metformin) unless contraindicated
• Proof that blood sugar isn’t adequately controlled on current therapy
• Insurers typically deny coverage if prescribed solely for weight loss in non-diabetic patients

Processing time: Initial PA decisions usually come within 5-7 business days, though appeals can take 2-3 weeks or longer.

What About Tier Placement and Copays?

When covered, these medications are typically placed in Tier 3 (non-preferred brand) or Tier 4 (specialty) on formularies. What does this mean for your wallet?

• Tier 3: You might pay 30-50% coinsurance or a copay of $75-$150 per month
• Tier 4 (Specialty): Coinsurance can be 25-33%, potentially translating to $300-$400+ out-of-pocket monthly on a $1,200 list price drug

Many commercial plans also have quantity limits (typically 4 pens per 28 days for maintenance doses) to prevent overuse or off-label prescribing.

Medicare Coverage: The Federal Exclusion Problem

Medicare Part D Does NOT Cover Weight-Loss Drugs

Here’s the hard truth: Traditional Medicare Part D excludes drugs ‘used for weight loss’ by federal law under the Social Security Act. This means:

• Wegovy is not covered under standard Part D for weight loss, period
• Zepbound (tirzepatide for obesity) is likewise excluded
• The exclusion applies regardless of how medically necessary the medication is for treating obesity

The one major exception: In March 2024, Medicare began covering Wegovy for patients who meet specific cardiovascular risk criteria—essentially, if you’re obese and have established cardiovascular disease, Wegovy can be covered as a heart medication, not a weight-loss drug. This narrow pathway helps some patients but leaves most without coverage.

What About Ozempic and Mounjaro on Medicare?

Good news here: If you have Type 2 diabetes, Medicare Part D plans do cover Ozempic and Mounjaro as diabetes medications. They’re subject to:

• Prior authorization confirming diabetes diagnosis
• Step therapy requirements (trying metformin or other first-line drugs first)
• Tier 3 or specialty tier copays

However, Medicare will deny coverage if these drugs are prescribed off-label for weight loss in someone without diabetes.

Medicare Advantage (Part C) Plans

Some Medicare Advantage plans started offering limited obesity drug coverage in 2025, but these are exceptions. Most MA plans follow traditional Medicare rules and exclude weight-loss medications. Always check your specific MA plan’s formulary—a small but growing number are adding coverage for Wegovy/Zepbound under strict criteria as an added benefit.

Medicaid Coverage: A Patchwork of State Policies

Medicaid coverage for weight-loss GLP-1s varies dramatically by state—and the landscape is shifting rapidly in 2025.

States That Cover Weight-Loss Drugs (with Heavy Restrictions)

As of late 2024, approximately 13 states offered some Medicaid coverage for medications like Wegovy, but many are now rolling back due to budget pressures. Here’s what you need to know about key states:

California (Medi-Cal):

• Covered in 2025 with PA, requiring BMI ≥30 (or ≥27 with comorbidity) and 6 months of supervised diet attempts
• Major change: Coverage ends January 1, 2026 for adults due to state budget cuts (approximately $27 million saved annually)
• Pediatric patients under 21 may still access coverage under EPSDT (Early and Periodic Screening, Diagnostic and Treatment) protections

Pennsylvania:

• Currently covers Wegovy and Zepbound with strict PA criteria (BMI ≥30 or ≥27+comorbidity, documented lifestyle attempts)
• Patients with diabetes must try diabetes-indicated GLP-1s first (step therapy)
• Upcoming change: Pennsylvania announced it will discontinue covering GLP-1 weight-loss drugs in January 2026 to control costs

New York:

• Covers Wegovy with prior authorization under the NYRx formulary
• Requires documentation of obesity diagnosis, lifestyle modification attempts, and adherence to FDA-approved criteria
• Quantity limits of 4 pens per 28 days apply
• Coverage remains in place as of early 2025, though subject to ongoing budget review

States That Do NOT Cover Weight-Loss Drugs

Texas:

• Excludes all obesity medications for adults (age 21+) under Medicaid
• This includes Wegovy, Saxenda, Qsymia, and similar drugs
• Children under 21 can request case-by-case exceptions through EPSDT, but adult coverage is prohibited

Florida:

• Utilizes the federal optional exclusion for weight-loss drugs
• No Medicaid coverage for any anti-obesity medications
• Only diabetes-indicated GLP-1s (Ozempic, Mounjaro) are covered, and only for Type 2 diabetes treatment

Illinois:

• Does not cover weight-loss drugs through Medicaid as of 2025
• A 2023 law expanded coverage for state employees but did not extend to Medicaid enrollees

Important Medicaid Notes

All states that do cover obesity drugs require:

• Strict prior authorization with BMI documentation
• Proof of lifestyle intervention attempts (typically 6 months of supervised diet and exercise)
• Regular monitoring and re-authorization to confirm weight loss progress
• Step therapy in many cases (trying older, cheaper medications first)

Even in states with coverage, pediatric patients (under age 21) often have better access through EPSDT protections, which mandate coverage of medically necessary treatments for children regardless of adult formulary rules.

Common Reasons for Insurance Denials—and How to Fight Back

Understanding why claims get denied is the first step to overturning them. Here are the top reasons:

1. Not Meeting Medical Necessity Criteria

Your documented BMI doesn’t hit the threshold (need ≥30, or ≥27 with qualifying comorbidity), or your weight-related health conditions aren’t recognized by your plan. Solution: Work with your doctor to thoroughly document your medical history, including all comorbid conditions (diabetes, hypertension, sleep apnea, dyslipidemia, etc.) and current BMI with official measurements.

2. Insufficient Documentation of Lifestyle Intervention

Most plans require proof of supervised weight-loss attempts—not just ‘I tried dieting,’ but actual physician records of a 6-month structured program. Solution: If you haven’t formally documented attempts, start a supervised program now and reapply. Retroactive documentation (notes from past visits showing diet counseling) can sometimes suffice if your doctor provides a detailed letter.

3. Step Therapy Requirements Not Met

Many insurers want you to try cheaper alternatives first—older weight-loss meds, or for diabetes patients, trying metformin before moving to expensive GLP-1s. Solution: Ask your doctor if you’ve already tried these medications (or have contraindications) and ensure this is clearly stated in the PA request.

4. Off-Label Use for Non-Approved Indication

Requesting Ozempic or Mounjaro for weight loss alone (without diabetes) will almost always be denied. Solution: If you have pre-diabetes, insulin resistance, PCOS, or other metabolic conditions, your doctor can potentially frame the prescription as treating those conditions, though success varies by plan.

5. Plan Exclusion of Weight-Loss Drugs

If your policy explicitly excludes ‘drugs for weight loss’ or ‘weight control,’ denials are automatic regardless of medical need. Solution: Appeals may succeed if you can argue the medication treats a covered condition (e.g., heart disease risk, not just obesity). Otherwise, you’ll need to explore self-pay options or ask your employer to add coverage.

How to Appeal a Denial Successfully

Step 1: Request a detailed denial letter explaining the specific reason.

Step 2: Gather supporting documentation:

• Complete medical records showing BMI history, comorbidities, and prior treatment attempts
• A letter of medical necessity from your physician explaining why this medication is essential for your health
• Any lab results (A1c, cholesterol panels, etc.) showing health risks related to weight
• Evidence of medication trials or lifestyle interventions

Step 3: Submit a formal written appeal within the timeframe specified (usually 30-180 days depending on your plan).

Step 4: Follow up aggressively—call weekly to check status and provide any additional requested information immediately.

Step 5: If the internal appeal fails, you have the right to an external review by an independent third party in most states. Don’t give up after one denial.

Success rates: While exact data varies, industry reports suggest that 20-30% of initial PA denials for GLP-1 weight-loss drugs are overturned on first appeal when patients provide complete documentation meeting criteria. Persistence pays off.

Self-Pay Options: New Affordable Pathways in 2025

If insurance won’t cover your GLP-1 medication, you’re not out of options. Recent manufacturer price reductions and discount programs have made these drugs more accessible than ever for self-pay patients.

GoodRx Partnership with Novo Nordisk

In November 2025, GoodRx launched a groundbreaking program offering:

Wegovy:

• $199/month for the first two months
• $349/month ongoing for most maintenance doses
• Available at nearly all pharmacies nationwide
• Represents a ~70% discount off list price

Ozempic:

• Same pricing structure: $199/month intro, $349/month ongoing (for 0.25-0.5mg doses)
• Higher 2mg dose runs ~$499/month
• Can be used by patients for diabetes management or weight loss

This partnership is a game-changer for the estimated 40% of Americans whose insurance doesn’t cover obesity medications.

Manufacturer Savings Cards

Novo Nordisk Programs:

• Savings Card (with insurance): Reduces copay to as low as $0-$25 per month (up to $225 monthly savings) for commercially insured patients
• Cash-Pay Program (NovoCare): Self-pay patients can access Wegovy for $349/month directly through Novo’s program (down from $499 earlier in 2025)
• Patient Assistance Program: Free medication for uninsured patients meeting income criteria (typically <400% of federal poverty level)

Eli Lilly Programs (for Mounjaro/Zepbound):

• Savings Card (for diabetes): $25/month for commercially insured patients with Type 2 diabetes (saves ~$500+ monthly)
• Cash-Pay Options: Lilly’s LillyDirect program offers single-dose Zepbound vials for $299-$449/month (depending on dose)
• Patient Assistance: Free or low-cost medication for qualifying uninsured patients

Important: Manufacturer savings cards typically cannot be combined with government insurance (Medicare, Medicaid) due to federal anti-kickback laws, but they work with most private plans.

Other Cost-Saving Strategies

Compare Pharmacy Prices: Cash prices can vary by hundreds of dollars between chains. Use GoodRx, SingleCare, or other coupon platforms to find the lowest price in your area.

Consider Lower-Cost Alternatives: Older FDA-approved weight-loss medications like phentermine ($30-$50/month), orlistat ($50-$100/month), or combination drugs (Qsymia, Contrave) cost far less and may be covered by insurance with lower copays.

Compounded Versions: Some telehealth providers and compounding pharmacies offer semaglutide or tirzepatide at reduced prices ($200-$400/month). Caution: These are not FDA-approved products and may carry quality, safety, and efficacy risks—the FDA has issued multiple warnings about compounded GLP-1s.

Patient Assistance Programs: Both Novo Nordisk and Eli Lilly offer comprehensive PAPs providing free medications to eligible low-income patients. Requirements typically include proof of income, lack of insurance coverage, and U.S. residency.

Telehealth Coverage: Good News for Access

One bright spot in this complicated landscape: Most insurance plans now cover telehealth visits for weight management just as they would in-person consultations.

Why This Matters

Thanks to pandemic-era policy changes that stuck, telehealth for chronic disease management—including obesity—is now widely reimbursed by commercial insurers, Medicare, and many Medicaid programs. Over 40 states have enacted telehealth parity laws requiring private insurers to cover virtual visits at the same rate as in-office visits.

What this means for you:

• Initial consultations, follow-up visits, and monitoring appointments can all happen via video or phone
• Most plans cover these visits with the same copay as regular office visits
• Nutritional counseling for obesity (an ACA-mandated preventive service) is covered with no cost-sharing when done via telehealth
• You can access specialists and weight-management programs that may not be available locally

Klarity Health and Telehealth Weight Management

Platforms like Klarity Health make accessing GLP-1 prescriptions more convenient by connecting you with licensed healthcare providers virtually. Here’s how it works in the insurance context:

• Transparent Pricing: Klarity Health offers both cash-pay and insurance-accepting options, so you know upfront what your visit will cost
• Provider Availability: Access to board-certified providers across multiple states means shorter wait times than traditional clinics (often same-day or next-day appointments)
• Dual Payment Options: Whether you’re using insurance for the visit and medication, or paying cash for everything, Klarity Health’s flexible model accommodates both approaches

After your virtual consultation, if a GLP-1 medication is prescribed, your provider sends the prescription to your preferred pharmacy—where you can then use your insurance (if covered) or apply manufacturer savings programs and discount coupons for the lowest price.

Important consideration: While telehealth visits are generally covered by insurance, the medication itself still requires prior authorization if billed to insurance. Klarity Health providers can help you navigate the PA process by providing necessary documentation, but approval depends on your specific plan’s criteria.

State-Specific Medicaid Coverage Reference Table

To help you quickly understand your state’s position, here’s a snapshot of priority states:

For diabetes medications (Ozempic, Mounjaro): Nearly all state Medicaid programs cover these when prescribed for Type 2 diabetes, though PA confirming diagnosis and prior therapy attempts is standard.

Key Takeaways: What You Need to Know Now

Insurance Coverage Reality Check

1. Commercial insurance varies wildly—diabetes GLP-1s are usually covered, but weight-loss drugs face restrictions or outright exclusions depending on your employer plan
2. Medicare Part D does not cover weight-loss medications except in narrow cardiovascular risk scenarios; diabetes medications are covered
3. Medicaid coverage is state-by-state and shrinking in 2025-2026 as budget pressures mount—check your state’s current formulary
4. Nearly all coverage requires prior authorization with strict criteria (BMI thresholds, comorbidities, lifestyle intervention documentation)

Denial and Appeal Strategy

• Document everything: Medical records, BMI history, comorbidities, and supervised weight-loss attempts
• Appeal aggressively: First-level appeals have reasonable success rates when you meet actual medical criteria
• Know your plan: Read your policy’s formulary and PA requirements before requesting a prescription
• Get your doctor’s help: A detailed letter of medical necessity significantly improves approval chances

Self-Pay Is More Accessible Than Ever

• GoodRx pricing: $199-$349/month for Wegovy/Ozempic (vs. $1,000+ list price)
• Manufacturer programs offer $0-$25 copays for insured patients with savings cards
• Patient assistance programs provide free medications for qualifying uninsured, low-income patients
• Compare all options before paying full retail price—savings can exceed $10,000 annually

Telehealth Is Your Friend

• Insurance covers telehealth visits for weight management at the same rate as in-person care
• Platforms like Klarity Health offer convenient access to prescribers with transparent pricing and both insurance and cash-pay options
• Virtual care removes geographic barriers and reduces wait times for specialist consultations

Taking Action: Your Next Steps

If you’re considering a GLP-1 medication for weight loss or diabetes management, here’s what to do:

Step 1: Check Your Coverage
Call your insurance company or log into your online portal to verify:

• Whether Wegovy, Ozempic, or Mounjaro are on your formulary
• What tier they’re placed in (affects your copay)
• Prior authorization requirements and criteria
• Whether weight-loss drugs are excluded entirely

Step 2: Gather Documentation
Work with your current healthcare provider or a telemedicine platform to document:

• Current BMI and weight history
• Any weight-related comorbidities (diabetes, hypertension, sleep apnea, high cholesterol, etc.)
• Previous weight-loss attempts (diet programs, medications tried, etc.)
• Lab results showing metabolic dysfunction if applicable

Step 3: Explore Telehealth Options
Consider platforms like Klarity Health that offer:

• Quick access to licensed providers experienced with GLP-1 prescribing
• Both insurance and cash-pay options (transparent pricing so you can decide)
• Help navigating prior authorization if using insurance

Step 4: Have a Backup Plan
If insurance denies coverage:

• Immediately appeal with comprehensive medical documentation
• While waiting on appeal, price out self-pay options using GoodRx, manufacturer programs, and patient assistance
• Consider lower-cost alternative medications as a bridge

Step 5: Don’t Give Up
Weight management is a serious health issue. Whether you ultimately access these medications through insurance, manufacturer assistance, or affordable self-pay programs, the important thing is not letting insurance barriers prevent you from getting clinically effective treatment.

Ready to explore your options? Klarity Health connects you with experienced healthcare providers who can evaluate whether GLP-1 medications are right for you—and help you navigate insurance, prior authorization, or the most affordable self-pay pathways. With transparent pricing, provider availability across states, and acceptance of both insurance and cash payment, getting started is easier than ever.

Citations

📅 RESEARCH CURRENCY STATEMENT (Verified as of December 17, 2025)

1. Aetna Clinical Policy Bulletin – Weight Loss GLP-1 Agonists (May 2024)
   www.aetna.com – Official insurer prior authorization criteria detailing BMI requirements, 6-month supervised lifestyle intervention, and approval process for Wegovy/Saxenda coverage.

2. California Department of Health Care Services (DHCS) Medi-Cal Announcement (December 2025)
   www.cmadocs.org – Official notice that California Medicaid will discontinue coverage of Wegovy, Saxenda, and Zepbound for weight loss effective January 1, 2026, due to budget constraints.

3. KFF (Kaiser Family Foundation) Issue Brief – Medicaid Coverage of GLP-1s (November 2024)
   www.kff.org – Comprehensive research report finding that only approximately 13 states covered obesity GLP-1 medications as of 2024, with all requiring strict prior authorization and BMI criteria; includes federal exclusion analysis.

4. GoodRx Press Release via BusinessWire (November 17, 2025)
   www.businesswire.com – Official announcement of GoodRx partnership with Novo Nordisk offering introductory $199/month pricing for Wegovy and Ozempic, with ongoing $349/month pricing at participating pharmacies nationwide.

5. Pennsylvania Health Law Project (PHLP) – PA Medicaid Coverage Update (2024-2025)
   www.phlp.org – Details Pennsylvania Medicaid’s coverage criteria for weight-loss GLP-1s (BMI ≥30 or ≥27 with comorbidity, lifestyle documentation required) and subsequent December 2025 announcement via WESA Pittsburgh that coverage will end in January 2026 due to cost constraints.

Note: Verified coverage status and pricing are accurate as of December 17, 2025. Formularies and state Medicaid policies were cross-referenced with official sources including Texas HHSC Vendor Drug Program, Florida Medicaid AHCA guidelines, New York NYRx PDL, Reuters Medicare policy updates, and Fierce Pharma industry pricing announcements. Always verify current coverage details with your specific insurance plan, as policies can change with new plan years.

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499